INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2004

High-dose nicotinamide did not prevent or delay the onset of type 1 diabetes in at-risk relatives.

In a randomized double-blind placebo-controlled trial across Europe, Canada, and the USA, 552 relatives of individuals with type 1 diabetes received oral modified release nicotinamide (1.2 g/m2) or placebo for 5 years. Over the trial, 159 participants developed diabetes (82 taking nicotinamide and 77 on placebo). The unadjusted hazard ratio was 1.07 (95% CI 0.78-1.45; p=0.69), and the adjusted hazard ratio was 1.01 (95% CI 0.73-1.38; p=0.97). Nicotinamide also did not affect growth in children, first-phase insulin secretion, or rates of serious adverse events.

Study type
Randomized double-blind placebo-controlled trial
Who was studied
552 relatives of people with type 1 diabetes with islet cell antibodies and non-diabetic glucose tolerance
What was measured
Development of type 1 diabetes defined by WHO criteria

THE PAPER

European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.

Gale EA, Bingley PJ, Emmett CL, Collier T, European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. Lancet, 2004.

PubMed 15043959 ↗DOI 10.1016/s0140-6736(04)15786-3 ↗

Diabetes & blood sugarNutrients & adequacy

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.